GLPwatch
Papers (9189)
Page 121 of 154, ranked by citation count.
- Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively.
- Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
- The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.
- Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.
- Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.
- GLP-1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy.
- Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
- Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.
- Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
- Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
- Neurological outcomes of antidiabetic therapy: What the neurologist should know.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.
- Comparing diabetes drugs--helping clinical decisions?
- Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity.
- Is liraglutide a useful addition to diabetes therapy?
- The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
- The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.
- Evolving directions in obesity management.
- Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
- Deciphering the Effects of Semaglutide Across the Glycemic Spectrum.
- Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.
- Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.
- Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.
- Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
- Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
- Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice.
- Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
- Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
- Incretin-induced changes in the transcriptome of skeletal muscles of fa/fa Zucker rat (ZFR) with obesity, without diabetes.
- Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence.
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.
- Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice.
- Understanding the Benefit of Combining GLP-1 Agonists With Exercise: Time Will Tell.
- Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.
- Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
- Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).
- Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.
- Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.
- Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
- Intragastric injection botulinum toxin A for obesity management with or without liraglutide.
- Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
- Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction.
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.
- Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.
- [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
- [Successful treatment with liraglutide in type 1 diabetes and MODY].
- Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
- Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
- Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.
- Glucagon-like peptide-1 agonists.
- Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
- Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
- Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.
- The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
- A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.